Matthew Meriggioli, M.D.

Grant effective: March 2011

Matthew Meriggioli, now a senior investigator at Novartis Institutes for BioMedical Research in Cambridge, Mass., received a three-year grant totaling $530,480 from MDA’s translational research program to study an immune system modulator called GM-CSF in a mouse model of myasthenia gravis (MG) and to conduct a clinical trial of the drug in a small group of patients with the disorder. At that time (March 2011), he was at the University of Illinois, Chicago.